Pediatric Stem Cell Transplant and Bone Marrow Transplant in China: CCBMTR 2017–2024 Registry Data on Haploidentical Donors, PBSC, Aplastic Anemia, Thalassemia, and Leukemia — For International Families and Physicians Seeking Second Opinion or Bone Marrow Transplant Evaluation in China

The CCBMTR snapshot covers eight years of activity across a national pediatric transplant system that has grown substantially during the registry period. The infrastructure data reflects sustained, systematic expansion:

For international families evaluating whether to seek a transplant assessment in China, this context matters. The registry reflects a system with substantial cumulative institutional experience, particularly in the indications detailed below. This article is part of ChinaMed Waypoint's pediatric leukemia and blood disorders resources for international families navigating complex transplant decisions.

For physicians familiar with European or North American pediatric transplant practice, the graft source distribution in the CCBMTR data is immediately striking. In many Western pediatric centers, bone marrow (BM) remains the preferred graft source for children. The Chinese registry documents a strikingly different pattern:

Cord blood (CB) use is modest overall but highly indication-specific. The registry documents CB as a major graft source in conditions where its biological properties offer particular advantages — such as inborn errors of metabolism (IEM) including mucopolysaccharidoses, where unrelated cord blood may deliver higher enzyme activity.

For haploidentical donors specifically, approximately two-thirds of HID PBSC transplants use combined-graft strategies — PBSC together with bone marrow, third-party cord blood, or mesenchymal stem cells (MSCs). This is a distinctive feature of Chinese haploidentical transplant protocols and differs from the post-transplant cyclophosphamide (PTCy) approaches more commonly used in Western haploidentical centers.

The shift in donor type across the eight-year registry period is one of its most clinically significant trends. Haploidentical donors — typically parents or siblings sharing approximately 50% HLA compatibility — rose from 42% to 56%, while matched sibling donors (MSD) declined from 28% to 15%. Unrelated donors (UD) remained at approximately 30%, compared with roughly 41% in the United States.

Several factors are cited in the published analysis for the decline in MSD use: China's smaller average family size, increasing germline cancer-predisposition screening, and carrier exclusion in children with inherited blood disorders. The 2014 Chinese consensus guidelines — authorizing matched unrelated donor (MUD) HCT as a first-line option for pediatric severe aplastic anemia — also contributed to shifting donor selection patterns across the country.

For families whose child has no matched sibling donor, the registry data reflects an established clinical framework — not an experimental workaround. Chinese centers have accumulated substantial experience with haploidentical transplant pathways across a wide range of indications, including non-malignant disease.

The registry shows a broadly distributed indication mix, with four conditions each representing approximately 17–19% of the total caseload. This distribution is itself significant: it reflects the breadth of non-malignant conditions — not just leukemia — being managed through transplant in Chinese pediatric centers.

The central message of the CCBMTR registry analysis — as summarized by the paper's authors — is that haploidentical PBSC transplantation is no longer a fallback platform in Chinese pediatric hematology. It is the operational backbone of an entire national program, including for non-malignant disease.

This has practical relevance for international families in situations where:

A structured review with a Chinese pediatric transplant team can help families understand what options exist and what an evaluation would involve — before any travel commitment. More context on the donor shortage decision process is available in our guide on what to do when a child has no matched donor.

The CCBMTR data raises a meaningful clinical question posed by the registry authors themselves: how transferable is the Chinese HID-PBSC pediatric model — particularly in aplastic anemia and thalassemia — to centers where bone marrow remains the pediatric default?

These differences reflect distinct institutional trajectories, protocol histories, and donor pool realities — not clinical superiority claims in either direction. The registry does not capture long-term outcomes data, and the authors acknowledge that harmonized post-transplant benchmarking across CIBMTR, EBMT, and CCBMTR represents the next frontier for meaningful international comparison. Families and physicians seeking to understand what a Chinese center's evaluation would specifically involve may consider a cancer treatment coordination pathway as a starting point.

For children undergoing hematopoietic cell transplant — a physically and emotionally intensive process for the whole family — supportive care is an important component of the treatment environment. In China, integrative supportive approaches may be available alongside standard hematology and transplant care, including nutritional support, fatigue and sleep management, and in some settings, Traditional Chinese Medicine approaches offered as complementary support during or after transplant.

Families interested in understanding the full care environment — including supportive care resources — can discuss this as part of a pre-evaluation consultation. More information on integrative and supportive approaches is available in our supportive care and Traditional Chinese Medicine resources.

Frequently Asked Questions